Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
108 hedge funds and large institutions have $757M invested in Epizyme, Inc in 2017 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 40 increasing their positions, 19 reducing their positions, and 13 closing their positions.
111% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 19
100% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 13
15% more call options, than puts
Call options by funds: $2.59M | Put options by funds: $2.24M
14% more funds holding
Funds holding: 95 → 108 (+13)
8% less capital invested
Capital invested by funds: $823M → $757M (-$65.9M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$13.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$9.96M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$9.74M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$9.15M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$8.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$19.9M |
| 2 |
DM
Deerfield Management
New York
|
-$11.4M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$6.8M |
| 4 |
QF
QVT Financial
New York
|
-$6.1M |
| 5 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$3.39M |
EPZM Hedge Fund Activity: Q2 2017 in Review
108 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q2 2017, worth a combined $757M — down 8% from $823M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new EPZM positions and 13 closed out — a net gain of 13 holders — while 40 added to existing stakes and 19 trimmed.
The largest buyer was Palo Alto Investors, adding an estimated $13.7M. The largest seller was Fidelity Investments, cutting an estimated $19.9M.
- 108 institutional investors held Epizyme, Inc (EPZM) as of Q2 2017, up from 95 in Q1 2017.
- Funds reported $757M of Epizyme, Inc stock for Q2 2017, down 8% quarter-over-quarter.
- 26 funds opened new Epizyme, Inc positions in Q2 2017 and 13 closed out, a net change of +13 holders.
- The largest Epizyme, Inc buyer in Q2 2017 was Palo Alto Investors, an estimated $13.7M added.
- The largest Epizyme, Inc seller in Q2 2017 was Fidelity Investments, an estimated $19.9M sold.
Based on aggregated 13F filings for Q2 2017.